Randomized comparison of Ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy - Design and rationale of the intracoronary stenting and antithrombotic regimen: Rapid early action for coronary treatment (ISAR-REACT) 5 trial

Stefanie Schulz, Dominick J. Angiolillo, David Antoniucci, Isabell Bernlochner, Christian Hamm, Juliane Jaitner, Karl Ludwig Laugwitz, Katharina Mayer, Barbara Von Merzljak, Tanja Morath, Franz Josef Neumann, Gert Richardt, Judith Ruf, Gisela Schömig, Helmut Schühlen, Heribert Schunkert, Adnan Kastrati

Research output: Contribution to journalArticlepeer-review

85 Scopus citations

Abstract

In acute coronary syndromes (ACS), a dual antiplatelet regimen with an adenosine diphosphate (ADP) receptor antagonist plus aspirin has become the cornerstone of treatment. The third-generation thienopyridine prasugrel and the cyclopentyl-triazolo-pyrimidine ticagrelor provide a greater, more rapid and consistent platelet inhibition compared to their predecessor clopidogrel. Based on their advantages over clopidogrel in two landmark studies, both drugs received a class I recommendation for their use in ACS patients with and without ST segment elevation. Due to differences in ACS populations and conditions investigated, the relative merits of ticagrelor versus prasugrel in the treatment of ACS patients with planned invasive strategy cannot be reliably estimated from independent trials. To date, no direct head-to-head comparison of ticagrelor and prasugrel in terms of clinical outcome exists. The aim of this multicenter, randomized, open-label trial is to assess whether ticagrelor is superior to prasugrel in ACS patients with planned invasive strategy.

Original languageEnglish
Pages (from-to)91-100
Number of pages10
JournalJournal of Cardiovascular Translational Research
Volume7
Issue number1
DOIs
StatePublished - Feb 2014

Keywords

  • Acute coronary syndrome
  • PCI
  • Prasugrel
  • Ticagrelor

Fingerprint

Dive into the research topics of 'Randomized comparison of Ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy - Design and rationale of the intracoronary stenting and antithrombotic regimen: Rapid early action for coronary treatment (ISAR-REACT) 5 trial'. Together they form a unique fingerprint.

Cite this